Table 1 Clinical characteristics of patients
|  | Total (N = 658) |
|---|---|
Age (years, median (IQR)) | 54.00 (48.00, 61.00) |
Menopause | |
Yes | 406 (61.7) |
No | 231 (35.1) |
Unknown | 21 (3.2) |
BMI (kg/m2, median (IQR)) | 22.52 (20.55, 24.63) |
Comorbidity | |
Yes | 228 (34.7) |
No | 430 (65.3) |
Type | |
Serous | 555 (84.3) |
Other | 103 (15.7) |
Grade | |
High | 553 (84.0) |
Other | 105 (16.0) |
FIGO stage | |
IIIC | 423 (64.3) |
IV | 235 (35.7) |
CA125 (U/ml, median (IQR)) | 1395.70 (638.50, 3180.00) |
Ascites | |
Yes | 537 (81.6) |
No | 114 (17.3) |
Unknown | 7 (1.1) |
Operation time (mins, median (IQR)) | 203.00 (160.00, 280.00) |
Blood loss (ml, median (IQR)) | 300.00 (200.00, 600.00) |
Surgical procedure | |
Upper abdominal surgery | 75 (11.4) |
Bowel resection | 90 (13.7) |
Lymphadenectomy | 343 (52.1) |
Residual disease | |
R0 | 297 (45.1) |
R1 | 240 (36.5) |
R2 | 121 (18.4) |
Postoperative complication | |
Yes | 333 (50.6) |
No | 325 (49.4) |
Hospitalization (days, median (IQR)) | 16 (14, 20) |
NACT cycles (median (IQR)) | 2 (2, 3) |
Chemotherapy regimen | |
Platinum + Paclitaxel | 646 (98.2) |
Other | 12 (1.8) |
Total cycles (median (IQR)) | 7 (6, 9) |